Assessment of the effectiveness of antiretroviral therapy in the Russian Federation in 2023


DOI: https://dx.doi.org/10.18565/epidem.2025.15.4.16-21

Yurin O.G., Ladnaia N.N., Kravchenko A.V., Sokolova E.V., Kozyrina N.V., Narsiya R.S., Shakhgildyan V.I., Pokrovsky V.V.

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia
Study objective: To assess the potential therapeutic and prophylactic efficacy of antiretroviral therapy (ART) achieved in Russia in 2023.
Materials and methods. Responses to questions on ART monitoring in response to a special Rospotrebnadzor request, «On the Causes of HIV Infection and Causes of HIV-Associated Mortality in the Russian Federation» for 2022―2023 were collected from 89 constituent entities of the Russian Federation.
Results. In 2023, 826,108 HIV-infected patients were registered for follow-up care (24,043 of them in four recently reunified regions). CD4 cell count coverage was 90.3% (23.8% in the reunified regions), and ART coverage was 88.8% and 78.4%, respectively. The number of HIV RNA copies in the blood (viral load, VL) below the detection level was observed in 55.3% of those registered for dispensary care and in 67.7% of those receiving ART (in the reunited regions, the figures are 18.9% and 32.6%, respectively). Of the 733,356 patients who started ART in 2023, 73.3% were tested for VL. VL was below the detection level in 92.3% of those tested (67.7% of those receiving ART). Virological failure of ART was confirmed in 6,654 people. Of these, 68.8% were switched to second-line ART regimens. 5.2% of patients discontinued ART (including due to death) in 2023. In the four reunified regions of the Russian Federation, almost all indicators of HIV care and treatment coverage, laboratory monitoring of its effectiveness, and resistance development were lower than the national average.
Conclusion. Not all HIV-positive Russians under observation follow-up and receiving ART are receiving ART efficacy monitoring based on changes in CD4 cell counts and viral load. Not all achieve undetectable viral loads. Furthermore, many patients with detectable viral loads do not change their ART regimen. Therefore, the effectiveness of ART for both treatment and prevention of HIV transmission remains insufficient.
Keywords: reunified territories of the Russian Federation, treatment as prevention, HIV prevention, HIV treatment, clinical follow-up, CD4 lymphocytes, ART, viral load, HIV infection
Read entire article

Literature

1. Cohen M., Chen Y., McCauly M., Gamble T., Hossienipour M., Kumrasamy N. Prevention of HIV-1 infection witн early antiretroviral therapy. N. Engl. J. Med. 2011; 365(6): 493–505. DOI: 10/1056/NEJMoa1105243


2. Newman C.E., de Wit J., Persson A., Holt M., Slavin S., Kidd M.R. Understanding Concerns About Treatment-as-Prevention Among People with HIV who are not Using Antiretroviral Therapy. AIDS Behav. 2015; 19(5): 821–831. DOI: 10.1007/s10461-014-0959-9


3. Покровский В.В., Ладная Н.Н. Вирус иммунодефицита человека в Российской Федерации в 2023 г. Эпидемиол. инфекц. болезни. Актуал. вопр. 2024; 14(3): 21–29. DOI: 10.18565/epidem.2024.14.3.21–9


Pokrovsky V.V., Ladnaia N.N. (Human immunodeficiency virus in the Russian Federation in 2023). Epidemiology and infectious diseases. Current items 2014; 14(3): 21–29. (In Russ.). DOI: 10.18565/epidem.2024.14.3.21-9


4. ВИЧ-инфекция у взрослых. Клинические рекомендации. 2024. https://diseases.medelement.com/disease


(HIV infection in adults. Clinical guidelines). (In Russ.). 2024. https://diseases.medelement.com/disease


5. ВИЧ-инфекция у детей. Клинические рекомендации. 2024. https://diseases.medelement.com/disease


(HIV infection in children. Clinical guidelines). 2024. (In Russ.). https://diseases.medelement.com/disease


6. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Шахгильдян В.И. и др. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ. Национальная ассоциация специалистов по инфекционным болезням имени академика В.И. Покровского. Эпидемиол. инфекц. болезни. Актуал. вопр. 2024; 14(4, приложение): 108 с.


Pokrovsky V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Ermak T.N., Shakhgildyan V.I. et al. (Recommendations for the treatment of HIV infection and related diseases, chemoprophylaxis of HIV infection). Academician V.I. Pokrovsky National Association of Infectious Diseases Specialists. Epidemiоlоgy and infectious diseases. Сurrent items 2014; 14(4, appendix), 108 p. (In Russ.).


7. Кравченко А.В., Ладная Н.Н., Шахгильдян В.И., Козырина Н.В., Юрин О.Г, Соколова Е.В. и др. Причины летальных исходов среди инфицированных вирусом иммунодефицита человека в 2022–2023 гг. Эпидемиол. инфекц. болезни. Актуал. вопр. 2025; 15(3): 6–12. DOI: 10.18565/epidem.2025.15.3.6-12


Kravchenko A.V., Ladnaia N.N., Shakhgildyan V.I., Kozyrina N.V., Yurin O.G., Sokolova E.V. et al. (Causes of deaths among people infected with the human immunodeficiency virus in 2022–2023). Epidemiоlоgy and infectious diseases. Сurrent items 2025; 15(3): 6–12. (In Russ.). DOI: 10.18565/epidem.2025.15.3.6-12


About the Autors

Oleg G. Yurin, МD, Leading Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being. Moscow, Russia; oleg_gerald@mail.ru; htpp://orcid.org/0000-0003-1930-7486
Natalia N. Ladnaya, Cand. Biol. Sci., Senior Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being, Moscow, Russia; ladnaia@hotmail.com; htpp://orcid.org/0000-0003-2994-151X
Professor Alexey V. Kravchenko, МD, Leading Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being. Moscow, Russia; alexey-kravtchenko@yandex.ru; http://orcid.org/0000-0001-7857-3763
Nadezhda V. Kozyrina, Cand. Med. Sci., Senior Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being, Moscow, Russia; nad-kozyrina@yandex.ru; htpp://orcid.org/0000-0001-5134-0054
Roza S. Narsia, Deputy Manager, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being. Moscow, Russia; rnarsiya @mail.ru; http://orcid.org/0000-0002-9514-7288
Ekaterina V. Sokolova, Cand. Med. Sci., Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being. Moscow, Russia; ekaterinasokolova007@rambler.ru, http://orcid.org/0000-0002-2001-8772
Professor Vadim V. Pokrovskiy, MD, Academician of the Russian Academy of Sciences; Head, Department of Epidemiology and Prevention of AIDS, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being. Moscow, Russia; pokrovsky.vad@yandex.ru; http://orcid.org/0000-0002-9514-7288


Similar Articles

Back to Content

Бионика Медиа